ERBB2 and breast carcinoma: Among the 75 patients with HER2-positive breast cancer, 25 received AC-TH, of which five developed metastasis; 20 received AC-T, of which 11 developed metastasis; eight received the TAC regimen, of which two developed metastasis; 12 received TCbH, of which two developed metastasis; and 10 received TCH, with no cases of metastasis.